Company Encyclopedia
View More
name
XDYY
301130.SZ
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.,Ltd engages in the research and development, production, and sale of chemical raw materials and pharmaceutical preparations in China. The company provides drugs for the treatment of anemia, mental disorders, cardiovascular and cerebrovascular diseases, and tumors. It provides drugs in the form of tablets and capsules. The company was founded in 1990 and is headquartered in Panshi, China.
3.096 T
301130.SZMarket value -Rank by Market Cap -/-

Financial Score

24/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking175/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE4.34%C
    • Profit Margin15.57%A
    • Gross Margin78.14%A
  • Growth ScoreC
    • Revenue YoY2.10%C
    • Net Profit YoY-9.07%C
    • Total Assets YoY7.80%B
    • Net Assets YoY5.44%B
  • Cash ScoreC
    • Cash Flow Margin642.38%C
    • OCF YoY2.10%C
  • Operating ScoreD
    • Turnover0.25D
  • Debt ScoreA
    • Gearing Ratio10.04%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    XDYY released its performance for the first three quarters, with a net profit attributable to the parent company of 33.1464 million yuan, a decrease of 2.7%

    XDYY released its third-quarter report for 2025, with operating revenue for the first three quarters amounting to 189 million yuan, a year-on-year decrease of 1.89%. The net profit attributable to the parent company was 33.1464 million yuan, a year-on-year decline of 2.70%. The net profit after deducting non-recurring gains and losses was 29.8086 million yuan, a year-on-year increase of 3.19%. The basic earnings per share were 0.4333 yuan

    Zhitong·
    SZ
    301130
    0.00%
    Zhitong·
    SZ
    301130
    0.00%

    XDYY: Obtained an invention patent certificate

    XDYY announced that the company recently obtained an invention patent certificate issued by the National Intellectual Property Administration of the People's Republic of China. The patent is titled "A Synthesis Method of Ruscogenin," with patent certificate number 8338136. The patent type is an invention patent, the application date is July 28, 2025, the authorization announcement date is October 10, 2025, the patent holder is Jilin Province XDYY Technology Development Co., Ltd., and the patent term is 20 years

    Zhitong·
    SZ
    301130
    0.00%
    Zhitong·
    SZ
    301130
    0.00%

    XDYY shareholders Hengqin Dingdian and Hengqin Runhuiyi plan to collectively reduce their holdings by no more than 3%

    According to the Zhitong Finance APP, XDYY announced that its shareholders Hengqin Dingdian and Hengqin Runhuiyi plan to reduce their holdings by no more than 2.2947 million shares, which is no more than 3% of the company's total share capital

    Zhitong·
    SZ
    301130
    0.00%
    Zhitong·
    SZ
    301130
    0.00%

    XDYY: Levofloxacin eye drops have obtained the drug registration certificate

    XDYY recently obtained the "Drug Registration Certificate" for levofloxacin eye drops issued by the National Medical Products Administration. This medication is used to treat various infectious diseases caused by sensitive bacteria, including blepharitis, meibomian gland inflammation, dacryocystitis, conjunctivitis, meibomian gland dysfunction, and keratitis

    Zhitong·
    SZ
    301130
    0.00%
    Zhitong·
    SZ
    301130
    0.00%

    XDYY: The pricing for the shareholder inquiry transfer is set at 24.69 yuan per share

    XDYY announced that based on the inquiry subscription situation as of June 30, 2025, the inquiry transfer price is set at 24.69 yuan per share. A total of 15 valid bids were received for this transfer, involving multiple professional institutional investors, with a total valid subscription of 3.72 million shares and a valid subscription multiple of 4.86 times. The shares to be transferred have been fully subscribed, with the transferees being 5 institutional investors, and the total number of shares to be transferred is 765,000 shares

    Zhitong·
    SZ
    301130
    0.00%
    Zhitong·
    SZ
    301130
    0.00%
    © 2025 Longbridge｜Disclaimer